Sophia George, PhD, and Judith E. Hurley, MD, walk through their study which found that 1 in 7 Caribbean-born adults with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, providing opportunities for targeted therapies and unique preventative approaches.
Ghaith Abu-Zeinah, MD, shares data from a retrospective study which indicated that interferon-alpha significantly improved myelofibrosis-free survival and overall survival over hydroxyurea (Hydrea) and phlebotomy only in patients with polycythemia vera.
Co-authors Toni K. Choueiri, MD and Robert J. Motzer, MD, discuss how data from the phase 3 CheckMate-9ER trial (NCT03121177) confirmed the advantage of frontline cabozantinib (Cabometyx) plus nivolumab (Opdivo) vs sunitinib (Sutent) in terms of survival and responses in patients with advanced renal cell carcinoma.
